下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Welcomes James Ott as Chief Technology Officer
CB Science,Inc.欢迎詹姆斯·奥特担任首席技术官

Accesswire ·  {{timeTz}}

Newly created position to spearhead technological innovation in the next stage of growth

设立新职位,引领下一阶段的技术创新

ESCONDIDO, CA / ACCESSWIRE / May 3, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces that effectively immediately James Ott has joined the Company's executive management team as its Chief Technology Officer. Mr. Ott brings to the enterprise deep industry experience with a seasoned background in research and development, product design, materials procurement, production operations, logistics, quality systems, and regulatory compliance.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2022年5月3日/CB Science。非侵入性动态心脏监护仪产品和服务的设计商、制造商和分销商CBSC(CBSC)(以下简称“CBSC”或“公司”)今天宣布,James Ott已立即加入公司的执行管理团队,担任首席技术官。奥特先生为企业带来了深厚的行业经验,在研发、产品设计、材料采购、生产运营、物流、质量体系和法规遵从性方面拥有丰富的背景。

"Jim has served in a number of key senior leadership positions during his esteemed twenty-eight-year career in the Ambulatory ECG and Clinical Research Trials arena, and we are elated that he has agreed to help lead us into our next phase of business expansion," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "I was quite fortunate to have worked with Jim in similar previous endeavors and based on that outstanding experience I am supremely confident his contributions to our future success will be both numerous and consequential."

CB Science,Inc.首席执行官查尔斯·马丁说:“吉姆在动态心电和临床研究试验领域的28年职业生涯中担任过多个重要的高级领导职位,我们很高兴他同意帮助我们进入下一阶段的业务扩展。我非常幸运地在以前的类似工作中与吉姆合作过,基于这一杰出的经验,我非常相信他将为我们未来的成功做出无数和重要的贡献。“

After earning his Master of Science in Biomedical Engineering at Marquette University in 1991, Mr. Ott joined Biomedical System as a Product Manager where he coordinated the design, development, and marketing efforts of their cardiac diagnostic software platform lines, including facilitation of regulatory submissions and inspection. He ultimately progressed to President of Biomedical Systems' Cardiology Division where he managed all aspects of their Independent Diagnostic Testing Facility (IDTF) including international direct and distributor capital equipment sales, IDTF cardiology lab staffing, technology, sales and marketing, customer service, reimbursements, and regulatory activities. Mr. Ott was also an integral contributor of successful U.S. patent submissions resulting in approvals granted for three applications in 2004, 2005, and 2013, each of which list him as one of the inventors.

1991年在马奎特大学获得生物医学工程理学硕士学位后,Ott先生加入Biomedical System担任产品经理,协调其心脏诊断软件平台系列的设计、开发和营销工作,包括促进监管提交和检查。他最终晋升为Biomedical Systems心脏病学部总裁,管理其独立诊断测试机构(IDTF)的方方面面,包括国际直销和分销商资本设备销售、IDTF心脏病学实验室人员配备、技术、销售和营销、客户服务、报销和监管活动。奥特先生也是成功提交美国专利的重要贡献者,在2004年、2005年和2013年,三项申请获得批准,每一项申请都将他列为发明者之一。

"I am very excited to join CB Scientific in this important new business leadership role and look forward to working for an organization that is so uniquely well-positioned to provide solutions that not only provide breakthroughs in technology, but also enable clinicians to take better care of patients while driving better operational, clinical, and financial outcomes," said Mr. Ott. "I am sincerely committed to expanding the Company's opportunities, both domestically and internationally, to affect real change in healthcare and enhancing value for our investors," he added.

奥特先生说:“我非常高兴能加入CB Science担任这一重要的新业务领导角色,并期待着为一个处于如此独特的有利地位的组织工作,该组织能够提供不仅提供技术突破的解决方案,而且使临床医生能够更好地照顾患者,同时推动更好的运营、临床和财务结果。”他补充说:“我真诚地致力于扩大公司在国内和国际上的机会,以影响医疗保健领域的真正变化,并提高我们投资者的价值。”

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,让其股东、行业参与者和公开市场了解情况。

About CB Scientific, Inc.

关于CB Science,Inc.

CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

CB Science,Inc.通过其国内和国际子公司,在动态非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件和适用于iOS和Android平台的智能手机应用程序为有异常心律风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:

公司联系信息:

Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电话:(888)225-0870
电子邮件:General Query:Info@cbScience ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com
关注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和时事通讯

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

这一信息披露可能包含《1995年私人证券诉讼法案》所涵盖的前瞻性陈述。这些前瞻性陈述涉及推出或增强我们的服务和产品的计划和时间,有关未来市场状况、供需状况的陈述,以及本新闻稿中包含的其他预期、意图和计划,这些都不是历史事实,涉及风险和不确定性。我们对未来收入的预期取决于我们开发和提供产品和服务的能力,这些产品和服务可能不是我们今天生产的,而且符合规定的规格。在本新闻稿中使用的“计划”、“预期”、“相信”以及类似的表述通常代表前瞻性陈述。这些声明反映了我们目前的预期。它们受到许多风险和不确定性的影响,包括但不限于技术的变化和普遍存在的市场的变化。本新闻稿包括1933年《证券法》第27A节和1934年《证券法》第27E节所指的前瞻性陈述。本新闻稿中包含的非历史事实的陈述可能被视为前瞻性陈述。请投资者注意,前瞻性陈述本质上是不确定的。由于某些风险和不确定因素,包括但不限于获得融资以及监管机构和股东对预期行动的批准的能力,实际业绩和结果可能与本文预测或建议的情况大不相同。

SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部